Search

Search Constraints

You searched for: Author/Creator Chan, Phyllis

Search Results

3. Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. (24th July 2014)

4. Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 2: Exposure–response analyses for efficacy and safety variables. (24th July 2014)

6. Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Issue 1 (25th August 2021)

7. Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation. (11th June 2022)

9. Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden. Issue 6 (25th November 2020)

10. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework. (4th August 2021)